A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus

Lupus

Volumn 26, Issue 14, 2017, Pages 1483-1490

  Chatham, W ^a   Chadha, A ^b   Fettiplace, J ^c   Kleoudis, C ^d   Bass, D ^e   Roth, D ^e   Gordon, D ^e  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b Austin Regional Clinic   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d PAREXEL INTERNATIONAL   (United States)

^e GLAXOSMITHKLINE   (United States)

Author keywords

belimumab; Pneumococcal; systemic lupus erythematosus; vaccination

Indexed keywords

ANTIMALARIAL AGENT; BELIMUMAB; CORTICOSTEROID; GSK BEL 115470; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENT; PNEUMOCOCCUS VACCINE; STEROID; TETANUS TOXOID; 23-VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE; AUTOANTIBODY; MONOCLONAL ANTIBODY;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTHRALGIA; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DOSE RESPONSE; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEVER; FOLLOW UP; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; OPEN STUDY; PHASE 4 CLINICAL TRIAL; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROTYPE; STEROID THERAPY; SUICIDE; SUICIDE ATTEMPT; SYSTEMIC LUPUS ERYTHEMATOSUS; TETANUS PROPHYLAXIS; TREATMENT RESPONSE; UNITED STATES; VACCINATION; ANTIBODY PRODUCTION; CLINICAL TRIAL; IMMUNOLOGY; MIDDLE AGED;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY FORMATION; AUTOANTIBODIES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PNEUMOCOCCAL VACCINES; SEROGROUP; VACCINATION;

EID: 85032827751     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203317703495     Document Type: Article

References (24)

1. Danza A, Ruiz-Irastorza G. Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies. Lupus 2013; 22: 1286–1294.
2. Bernatsky S, Boivin JF, Joseph L, Mortality in systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2550–2557.
3. Iliopoulos AG, Tsokos GC. Immunopathogenesis and spectrum of infections in systemic lupus erythematosus. Semin Arthritis Rheum 1996; 25: 318–336.
4. Murdaca G, Orsi A, Spano F, Influenza and pneumococcal vaccinations of patients with systemic lupus erythematosus: Current views upon safety and immunogenicity. Autoimmun Rev 2014; 13: 75–84.
5. Elkayam O, Paran D, Caspi D, Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Infect Dis 2002; 34: 147–153.
6. Borba EF, Saad CGS, Pasoto SG, Influenza A/H1N1 vaccination of patients with SLE: Can antimalarial drugs restore diminished response under immunosuppressive therapy? Rheumatology 2012; 51: 1061–1069.
7. Van Assen S, Agmon-Levin N, Elkayam O, Eular recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011; 70: 414–422.
8. FDA. Benlysta™ prescribing information 2014; www.accessdata.fda.gov/drugsatfda_docs/label/2012/125370s016lbl.pdf
9. Baker KP, Edwards BM, Main SH, Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 2003; 48: 3253–3265.
10. Stohl W, Hiepe F, Latinis KM, Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2328–2337.
11. La Cava A. Targeting the BLYS-APRIL signaling pathway in SLE. Clin Immunol 2013; 148: 322–327.
12. Furie R, Petri M, Zamani O, A Phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011; 63: 3918–3930.
13. Chatham WW, Wallace DJ, Stohl W, Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the bliss-76 trial. J Rheumatol 2012; 39: 1632–1640.
14. Nagel J, Saxne T, Geborek P, Treatment with belimumab in SLE does not impair antibody response to 13-valent pneumococcal conjugate vaccine. Arthritis Rheum 2015; 67: 2169–2169.
15. ICH. Good manufacturing practice guide for active pharmaceutical ingredients. http://www.ich.org/products/guidelines/quality/article/quality-guidelines.html (2000, accessed November 2016)
16. WMA. WMA Declaration of Helsinki - ethical principles for medical research involving human subjects. JAMA 2013; 310: 2191–2194. www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects
17. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725–1725.
18. American College of Rheumatology. Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology ad hoc committee on systemic lupus erythematosus guidelines. Arthritis Rheum 1999; 42: 1785–1796.
19. Bonilla FA, Bernstein IL, Khan DA, Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy, Asthma, Immunol 2005; 94: S1–S63.
20. Bingham CO, 3rd Looney RJ, Deodhar A, Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trial. Arthritis Rheum 2010; 62: 64–74.
21. Hare ND, Smith BJ, Ballas ZK. Antibody response to pneumococcal vaccination as a function of preimmunization titer. J Allergy Clin Immunol 2009; 123: 195–200.
22. Kamchaisatian W, Wanwatsuntikul W, Sleasman JW, Tangsinmankong N. Validation of current joint American Academy Of Allergy, Asthma & Immunology and American College Of Allergy, Asthma and Immunology guidelines for antibody response to the 23-valent pneumococcal vaccine using a population of HIV-infected children. J Allergy Clin Immunol 2006; 118: 1336–1341.
23. Agarwal S, Cunningham-Rundles C. Autoimmunity in common variable immunodeficiency. Curr Allergy Asthma Rep 2009; 9: 347–352.
24. Wallace D, Navarra S, Petri M, Safety profile of belimumab: Pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. Lupus 2013; 22: 144–154.